Myfortic Better For Kidney Patients
Novartis said on Wednesday its Myfortic transplant rejection treatment improved quality of life for kidney transplant patients switching to the drug from conventional treatments.
Novartis said a study showed that 66 percent of patients who suffered gastrointestinal complaints while on a conventional drug after surgery reported an improvement in their symptoms when they switched to Myfortic.